Masimo Corp. (NSDQ:MASI) announced positive results from a study on its carbon monoxide (CO) poisoning screening technology.
The Irvine, Calif.-based company reported that an independent study demonstrated that noninvasive Masimo carboxyhemoglobin (SpCO) measurements provide an "effective means for screening at-risk populations for CO poisoning" with "acceptable bias and precision" compared to invasive blood gas analysis. The results were published in the April issue of Annals of Emergency Medicine.
"The prospective diagnostic accuracy study is more than ten times larger than any other published SpCO accuracy study to date and provides a strong rationale for clinical use of SpCO in the evaluation of emergency department patients," according to the company.
The study was conducted over a year-long period in the Dept. of Emergency Medicine at the Vienna General Hospital and compared the accuracy of SpCO measured noninvasively using the Masimo Radical-7 with COHb measurements obtained via invasive blood gas analysis in 1,578 ED patients.
The symptoms of CO poisoning range from mild headache, nausea, confusion, and dizziness to myocardial infarction and stroke, so diagnosis is difficult and has historically relied on clinical suspicion and measurement of carboxyhemoglobin (COHb) via invasive blood gas analysis, Masimo said.
At least 20,000 known exposures and 439 deaths a year are attributed to non-fire-related, unintentional CO poisoning cases in the U.S., the company reports.
Here’s a roundup of recent clinical trial and scientific study news:
- Rhythmia Medical to present clinical data at Heart Rhythm Society 2011 conference
Rhythmia Medical Inc. announced that key results from its ongoing pre-clinical and clinical studies will be presented at the 2011 Annual Scientific Session of the Heart Rhythm Society in San Francisco. The results will highlight the safety, efficacy and utility of Rhythmia Medical’s mapping system, a technological breakthrough that can significantly improve cardiac ablation procedures by generating high resolution electroanatomical maps fast, simply and accurately.
- Lexington International touts HairMax hair growth studies and heralds FDA clearance
Lexington International LLC announced that it has successfully completed 2 clinical studies of the HairMax LaserComb proving the efficacy and safety of 3 new devices for the treatment of androgenetic alopecia (hereditary hair loss). The analysis showed that 95.4 percent of participants using the HairMax LaserComb experienced hair growth. Furthermore, the average increases in hair count for participants in the HairMax LaserComb group was 20.4 hairs per centimeter squared, which is considered medically and scientifically significant. None of the participants in the studies experienced any serious side effects. Based in part on submission of clinical results, the FDA granted 510(k) clearance of these medical devices for sale in the U.S. for the ‘Treatment of Hair Loss and Promotion of Hair Growth’ in males.
- ACT files for European trial for phase 1/2 study on stem cells for treating macular degeneration
Advanced Cell Technology Inc. (OTC:ACTC), a leader in the field of regenerative medicine, announced that it has filed a clinical trial application (CTA) with the European Medicines and Healthcare products Regulatory Agency (MHRA) seeking clearance to initiate its Phase 1/2 clinical trial using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt’s Macular Dystrophy (SMD).
- Harvest Technologies enrolls first patient in heart failure stem cell treatment study
Harvest Technologies Corp. announced that the first twelve patients of its sixty patient Heart Failure trial have been enrolled at Medanta-the Medicity in Gurgaon INDIA. The trial is intended to evaluate the safety and clinical effect of Harvest’s BMAC autologous cell composition to treat patients with Congestive Heart Failure (CHF) when using a minimally invasive retrograde coronary sinus delivery.
- Gore reports first patients treated in Australia using new endoprosthesis delivery system
W. L. Gore & Associates reported the first clinical uses in Australia of the GORE C3 Delivery System to deploy the GORE EXCLUDER AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA). The recent procedures were successfully performed by vascular surgeons at medical centers of excellence around Australia. This game-changing new technology represents a leap forward in medical innovation by allowing physicians to position the device to the specific anatomy of each individual patient.
- Jennerex and Green Cross tout data on JX-594 in combination with Sorafenib in advanced liver cancer
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea. The data were reported in the journal Molecular Therapy.
- Celera announces new findings on KIF6 and PMA application
Celera Corp. (NSDQ:CRA) provided an update on recent scientific findings pertaining to the KIF6 gene variant and its pre-market approval application (PMA) with the U.S. FDA for its KIF6 Genotyping Assay. In nine previously published peer-reviewed articles on genetic studies of KIF6, including 4 prospective randomized clinical trials of statin therapy (CARE, WOSCOPS, PROSPER, and PROVE IT), KIF6 carriers had greater risk for coronary heart disease (CHD) and received greater benefit from pravastatin therapy (or from high-dose atorvastatin compared with pravastatin in the PROVE IT trial) than did noncarriers. Two recent papers in peer-reviewed publications, and two posters presented at the annual meeting of the American College of Cardiology earlier this month, provided new information relative to KIF6 that differed in several important respects from the above-mentioned genetic studies.